Dr Reddys Laboratories (RDY) Receivables - Other (2021 - 2022)
Dr Reddys Laboratories (RDY) posted Receivables - Other of $531962.9 for Q1 2022, down 3.03% on a QoQ basis from $548595.0 in Q1 2021, and down 3.03% year-over-year from $548595.0 in Q1 2021.
Powered by 
Analysis
Dr Reddys Laboratories (RDY) Receivables - Other (2021 - 2022) Analysis & Trends
Dr Reddys Laboratories has reported Receivables - Other for 2 years, with the latest figure at $531962.9 in Q1 2022.
- On a quarterly basis, Receivables - Other fell 3.03% year-over-year to $531962.9 in Q1 2022; TTM through Mar 2022 was $531962.9, a 3.03% decrease from a year earlier, with the FY2022 full-year figure at $537016.3, changed 0.23% from the prior year.
- Receivables - Other was $531962.9 for Q1 2022 at Dr Reddys Laboratories, down from $548595.0 in the prior quarter.
- The five-year high for Receivables - Other was $548595.0 in Q1 2021, with the low at $531962.9 in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - |